View this email in your browser

Value-based agreements –
are we going to see more or less of them?

Tuesday, November 16, 12:00pm - 1:00pm EST

Value-based agreements (VBAs), Managed Entry Agreements (MEAs) or Outcomes-based agreements are arrangements between manufacturers and healthcare payers that allow for coverage of innovative treatments while managing uncertainty around financial impact or performance. VBAs are utilized to address payer concerns about the product’s clinical value. 

Over the past decade, much as been learned about the application of MEAs, including how to structure and assess their impact from the perspective of relevant stakeholders (manufacturers, payers, patients).  

In this webinar, we present an evidence-based summary of global experience with Managed Entry Agreements, Outcomes-based Agreements, and Risk-sharing Arrangements. Common challenges, actionable solutions and key learnings will be discussed using case studies and multiple examples. 

You’ll learn about how a value-based agreement announced between Prime Therapeutics and Pear Therapeutics is being utilized to support coverage of prescription digital therapeutics for substance and opioid use disorder, including stakeholder incentive alignment and financing considerations. Mike Pace, former Global Commercial Head of Market Access and HEOR of Pear Therapeutics will present this case study and its broader implications.

Pierre Etienne and Clifton Chow will describe how to define, measure and monitor relevant outcomes as part of MEAs, with multiple examples from the literature.  

At the end of this webinar, you will have a strong understanding of the types of financial and outcomes-based arrangements commonly utilized in the industry, including common pitfalls and possible solutions that drive success for the manufacturer, payer and patient. Join us for an insightful and practical webinar on one of the most important areas in pharmaceutical value and market access. 
Madhur Garg
Director, Global RWE and Market Access, LabCorp
Mike Pace
CEO & Founder, and prior Pear Therapeutics Head of Market Access & HEOR
Pierre Etienne
CMO & co-founder, Actu-Real
Clifton Chow
HEOR Consultant, Actu-Real

Patient-Centric RWE Research & Remote Monitored Care:
Learnings from a support program leveraging telehealth & connected devices

November 15, 2:00pm - 3:00pm EST

Preparing a Successful ICER Strategy:
Lessons from the Frontlines

November 17, 1:00pm - 2:00pm EST

Copyright © 2021, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp